Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2006

View Archived Issues

CE Mark for Tag-It Cystic Fibrosis Kit

ActivBiotics and Metaphore Pharmaceuticals complete merger

Pharmacopeia earns milestone payment in Organon collaboration

New multidose study of Riquent planned in lupus patients

Studies show BioThrax plus antibiotics protect animals post anthrax exposure

Japanese licensing deal for Fentanyl Taifun

Corautus Genetics to support study of VEGF-2 in critical limb ischemia

Salix offers development update

Duloxetine 60 mg once daily found safe and effective in fibromyalgia patients

GE-81112 factor B: A novel prokaryotic-specific protein synthesis inhibitor

Human Genome Sciences receives milestone for GSK-716155 IND filing

Mylan and Forest sign nebivolol agreement

Ablynx and Centocor sign Nanobodies agreement

Phase IIa study of ATL-1102 restarts

Safety data review in phase III study of Intercell's Japanese encephalitis vaccine

Russian approvals for HER-2 Protein AutoVac vaccine phase II trial

Placebo group assumptions correct in phase IIb study of VLTS-934 in intermittent claudication

Novel orally active CB1 receptor inverse agonist decreases food intake in rodents

Novel orally active and in vivo effective p38alpha MAPK inhibitors from Novartis

FDA issues guidance to improve efficiency of earliest stages of clinical testing

Recent patents report novel therapeutic agents for anxiety, depression, etc.

Novel possible treatment options for cancer disclosed in patent literature

First launch for Dong-A erectile dysfunction therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.